In keeping with these observations, patients with lupus prescribed ARBs were less likely to have the lupus-driven chromatin accessibility signature and had reduced transcriptional enrichment for the TNF-α signaling pathway. The gene discussed is TNF; the disease is systemic lupus erythematosus.